×
About 14,889,585 results

Breast Cancer Research at ASCO20 Virtual Scientific Program Highlights New Avenues and Better Outcomes
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200222/full/

Jun 25th, 2020 - The ASCO20 Virtual Scientific Program featured a variety of important and innovative breast cancer research. The following are some of the studies with potential to significantly impact clinical practice and patient outcomes, as selected by ASCO Daily News Expert Panel member Arielle Heeke, MD, of the Levine Cancer Institute.

Will DFS Benefit Translate Into Survival Benefit in ADAURA?
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200221/full/

Jun 24th, 2020 - The report on ADAURA during the ASCO20 Virtual Scientific Program Plenary Session surprised many, first because the initial data readout for the phase III trial was not planned until 2022 and second because of the strength of the disclosed data (Abstract LBA5). Early unblinding of the results revealed an 83% reduction in the risk of disease recurrence or death with use of adjuvant osimertinib c...

KRd, VRd Equivalency in Multiple Myeloma ‘Reassuring’ to Hematologists
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200219/full/

Jun 24th, 2020 - Awaited results of the ENDURANCE trial showed equivalency between a regimen of carfilzomib plus lenalidomide and dexamethasone (KRd) and bortezomib, lenalidomide, and dexamethasone (VRd) as an initial therapy for patients with standard- or intermediate-risk multiple myeloma (Abstract LBA3). KRd failed to improve progression-free survival compared with VRd, according to data presented by Shaji K...

Clinical Implications of First-Line Pembro for MSI-High mCRC
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200220/full/

Jun 24th, 2020 - Long-awaited results from the randomized, phase III KEYNOTE-177 trial provide strong support for using single-agent pembrolizumab instead of a chemotherapy-based regimen in patients newly diagnosed with metastatic colorectal cancer (mCRC) featuring high-level microsatellite instability (MSI-H) or deficient mismatch repair (dMMR; Abstract LBA4).

ECOG-ACRIN Trial Reassures Clinicians, Patients That Locoregional Therapy Is Not Beneficial for Stage IV Metastatic Breast Cancer
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200218/full/

Jun 24th, 2020 - For patients with stage IV metastatic breast cancer and an intact primary tumor (ITP), the early initiation of locoregional treatment (LRT) was not associated with longer survival or improvements in health-related quality of life (HRQoL) compared with systemic therapy alone, according to a phase III clinical trial (Abstract LBA2). These findings appear to add to a robust evidence base that sugg...

Switch Maintenance With Avelumab Changes Treatment Paradigm for Advanced Urothelial Carcinoma
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200217/full/

Jun 24th, 2020 - A switch maintenance therapy approach using the immune checkpoint inhibitor avelumab in patients with advanced urothelial carcinoma (UC) who had not progressed after induction platinum-based chemotherapy offered significantly improved survival outcomes, according to results of the JAVELIN Bladder 100 trial (Abstract LBA1). The study, which was the first UC study ever presented during an ASCO An...

Trastuzumab Achieves Slight Reduction in Recurrence for Women With HER2-Positive DCIS
https://ascopost.com/news/june-2020/trastuzumab-achieves-slight-reduction-in-recurrence-for-women-with-her2-positive-dcis/

Jun 8th, 2020 - The addition of trastuzumab to radiotherapy did not reach the protocol objective of a 36% reduction in the ipsilateral breast tumor recurrence rate for women with HER2-positive ductal carcinoma in situ (DCIS) in the NRG Oncology clinical trial NSABP B-43. The trial did find a modest (19%) reduction in the rate of recurrence among women who received trastuzumab, but this difference was not stati...

RET Kinase Inhibitor for Patients With Solid Tumors and RET Genetic Fusions
https://ascopost.com/news/june-2020/ret-kinase-inhibitor-for-patients-with-solid-tumors-and-ret-genetic-fusions/

Jun 5th, 2020 - The RET inhibitor pralsetinib showed activity in patients with a broad variety of tumors harboring RET gene fusions, according to results from the phase I/II ARROW trial, presented by Vivek Subbiah, MD, and colleagues during the ASCO20 Virtual Scientific Program (Abstract 109).

Results From an Oncology Hospital-at-Home Evaluation
https://ascopost.com/news/june-2020/results-from-an-oncology-hospital-at-home-evaluation/

Jun 5th, 2020 - Researchers at Huntsman Cancer Institute (HCI) at the University of Utah presented the first outcomes evaluation of an adult oncology hospital-at-home program during the ASCO20 Virtual Scientific Program (Abstract 7000). The study evaluated patients participating in HCI's Huntsman at Home program. The data demonstrated strong evidence for the benefits of this care model, showing improved patien...

Remote Pre- and Posttest Genetic Counseling for Breast and Ovarian Cancer Risk
https://ascopost.com/news/june-2020/remote-pre-and-post-test-genetic-counseling-for-breast-and-ovarian-cancer-risk/

Jun 2nd, 2020 - Genetic testing for cancer risk can significantly improve the prevention or treatment of hereditary cancers, but studies have shown that people who might have a genetic risk often don't get tested. A collaborative team of researchers have tested a possible solution through a clinical trial aimed at making genetic testing more accessible. The trial, called MAGENTA (Making GENetic Testing Accessi...

Cediranib/Olaparib vs Standard-of-Care Chemotherapy for Platinum-Sensitive Ovarian Cancer
https://ascopost.com/news/june-2020/cediranibolaparib-vs-standard-of-care-chemotherapy-for-platinum-sensitive-ovarian-cancer/

Jun 2nd, 2020 - Results of the NRG Oncology phase III clinical trial NRG-GY004 indicated that the addition of the investigational agent cediranib to olaparib and standard platinum-based chemotherapy did not improve progression-free survival outcomes for women with platinum-sensitive ovarian cancer; however, activity between the treatments was similar in patients. These results were recently presented by Joyce ...

Durvalumab Added to Standard Chemotherapy Improved Overall Survival in Patients With Malignant Pleural Mesothelioma
https://ascopost.com/news/june-2020/durvalumab-added-to-standard-chemotherapy-improved-os-in-patients-with-malignant-pleural-mesothelioma/

Jun 1st, 2020 - Data from clinical efficacy and biomarker analyses conducted for the single-arm phase II PrE0505 study of the initial treatment of patients with malignant pleural mesothelioma were presented by Patrick Forde, MB, BCh, and colleagues during the Lung Cancer Oral Abstract Session at the ASCO20 Virtual Scientific Program (Abstract 9003). The trial evaluated the addition of durvalumab, an immune che...

Carfilzomib vs Bortezomib in Addition to Lenalidomide/Dexamethasone in Newly Diagnosed Multiple Myeloma
https://ascopost.com/news/june-2020/carfilzomib-vs-bortezomib-in-addition-to-lenalidomidedexamethasone-in-newly-diagnosed-multiple-myeloma/

Jun 1st, 2020 - The combination of carfilzomib, lenalidomide, and dexamethasone (KRd) did not show superior efficacy in patients with newly diagnosed myeloma absent a high-risk disease prognosis, compared with the standard of care: bortezomib, lenalidomide, and dexamethasone (VRd). Data from a planned interim analysis for efficacy and toxicity in the randomized phase III ENDURANCE trial were presented in the P...

Alberto F. Sobrero, MD, on Colon Cancer: Adjuvant Oxaliplatin and Fluoropyrimidine-Based Therapy for Stage III Disease
https://ascopost.com/videos/asco20-virtual-scientific-program/alberto-sobrero-on-adjuvant-oxaliplatin-and-fluoropyrimidine-based-therapy-for-stage-iii-colon-cancer/

Jun 1st, 2020 - Alberto F. Sobrero, MD, of the Ospedale San Martino, discusses final results of the IDEA study, which supported the use of 3 months of adjuvant CAPOX, vs 6 months, for most patients with stage III colon cancer. The shorter treatment duration reduced toxicity, inconvenience, and cost (Abstract 4004).

Michael J. Morris, MD, on Prostate Cancer: Impact of PSMA-Targeted Imaging on Clinical Management
https://ascopost.com/videos/asco20-virtual-scientific-program/michael-morris-on-the-impact-of-psma-targeted-imaging-on-clinical-management-of-prostate-cancer/

Jun 1st, 2020 - Michael J. Morris, MD, of Memorial Sloan Kettering Cancer Center, discusses phase III data from the CONDOR trial, which showed that PSMA-targeted PET scans detected and localized occult disease in most men with biochemically recurrent prostate cancer presenting with negative or equivocal conventional imaging findings (Abstract 5501).

Neal D. Shore, MD, on Prostate Cancer: Relugolix vs Leuprolide for Advanced Disease
https://ascopost.com/videos/asco20-virtual-scientific-program/neal-shore-on-relugolix-vs-leuprolide-for-advanced-prostate-cancer/

Jun 1st, 2020 - Neal D. Shore, MD, of the Carolina Urologic Research Center, discusses phase III results of the HERO study, which showed relugolix achieved castration as early as day 4 and was superior to leuprolide in sustained testosterone suppression, testosterone recovery after discontinuation, and reduction in cardiovascular side effects (Abstract 5602).

Thierry André, MD, on Colorectal Cancer: Pembrolizumab vs Chemotherapy for Metastatic Disease
https://ascopost.com/videos/asco20-virtual-scientific-program/thierry-andre-on-pembrolizumab-vs-chemotherapy-for-metastatic-colorectal-cancer/

Jun 1st, 2020 - Thierry André, MD, of Hôpital Saint-Antoine, discusses the phase III results from KEYNOTE-177, which showed that, compared with standard chemotherapy of FOLFOX or FOLFIRI, pembrolizumab doubled median progression-free survival, from 8.2 months to 16.5 months, in patients with microsatellite instability–high/mismatch repair–deficient metastatic colorectal cancer (Abstract LBA4).

Rana R. McKay, MD, on Prostate Cancer: Intense Androgen-Deprivation Therapy Before Radical Prostatectomy
https://ascopost.com/videos/asco20-virtual-scientific-program/rana-mckay-on-intense-adt-before-radical-prostatectomy/

Jun 1st, 2020 - Rana R. McKay, MD, of the University of California, San Diego, discusses the results of a phase II trial of intense neoadjuvant hormone therapy followed by radical prostatectomy in men with high-risk prostate cancer. The data show that 21% of patients had a favorable pathologic response (Abstract 5503).

Early local therapy fails to extend survival in metastatic breast cancer subset
https://www.healio.com/hematology-oncology/breast-cancer/news/online/{fce1cd33-c5fd-4bf8-8336-97281967a80c}/early-local-therapy-fails-to-extend-survival-in-metastatic-breast-cancer-subset

Jun 1st, 2020 - Early local therapy did not prolong survival among women with de novo metastatic breast cancer and intact primary tumors, according to randomized phase 3 study results presented during the ASCO20 Virtual Scientific Program.

Adjuvant atezolizumab fails to extend DFS in high-risk urothelial carcinoma
https://www.healio.com/hematology-oncology/genitourinary-cancer/news/online/{9212b066-b10f-4746-bf88-5ea0cb25b1cf}/adjuvant-atezolizumab-fails-to-extend-dfs-in-high-risk-urothelial-carcinoma

Jun 1st, 2020 - Adjuvant atezolizumab failed to extend DFS compared with observation for patients with high-risk muscle-invasive urothelial carcinoma, according to randomized phase 3 study results presented during the ASCO20 Virtual Scientific Program.